Latest Insider Transactions at Wave Life Sciences Ltd. (WVE)
This section provides a real-time view of insider transactions for Wave Life Sciences Ltd. (WVE). The data is sourced from Form 4 filings with the SEC, which are filed by insiders of Wave Life Sciences Ltd. to disclose their transactions in the company's securities. By reviewing this information, investors can gain insights into the trading activity of Wave Life Sciences Ltd.'s insiders and make more informed investment decisions.
Insider Transaction List
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Nov 25
2024
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
50,000
-18.7%
|
$750,000
$15.0 P/Share
|
|
Nov 25
2024
|
Paul Bolno President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
50,000
+15.76%
|
$100,000
$2.48 P/Share
|
|
Nov 15
2024
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
51,234
-19.08%
|
$717,276
$14.32 P/Share
|
|
Nov 08
2024
|
Chris Francis |
SELL
Open market or private sale
|
Direct |
36,000
-100.0%
|
$576,000
$16.0 P/Share
|
|
Nov 08
2024
|
Chris Francis |
BUY
Exercise of conversion of derivative security
|
Direct |
36,000
+50.0%
|
$288,000
$8.17 P/Share
|
|
Oct 16
2024
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
90,474
-25.2%
|
$1,357,110
$15.0 P/Share
|
|
Oct 16
2024
|
Chris Francis |
SELL
Open market or private sale
|
Direct |
208,836
-100.0%
|
$2,714,868
$13.56 P/Share
|
|
Oct 16
2024
|
Chris Francis |
BUY
Exercise of conversion of derivative security
|
Direct |
129,122
+50.0%
|
$258,244
$2.82 P/Share
|
|
Oct 11
2024
|
Kyle Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
25,000
+35.83%
|
$50,000
$2.48 P/Share
|
|
Sep 27
2024
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
2,791,930
+14.27%
|
$22,335,440
$8.0 P/Share
|
|
Sep 25
2024
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
17,146
-46.44%
|
$154,314
$9.0 P/Share
|
|
Aug 21
2024
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
48,366
-11.87%
|
$241,830
$5.78 P/Share
|
|
Aug 12
2024
|
Ra Capital Management, L.P. |
BUY
Grant, award, or other acquisition
|
Indirect |
16,115
+50.0%
|
-
|
|
Aug 12
2024
|
Ken Takanashi |
BUY
Grant, award, or other acquisition
|
Direct |
16,115
+0.28%
|
-
|
|
Aug 12
2024
|
Heidi L Wagner |
BUY
Grant, award, or other acquisition
|
Direct |
32,230
+50.0%
|
-
|
|
Aug 12
2024
|
Gregory L. Verdine |
BUY
Grant, award, or other acquisition
|
Direct |
16,115
+25.9%
|
-
|
|
Aug 12
2024
|
Mark Corrigan |
BUY
Grant, award, or other acquisition
|
Direct |
32,230
+50.0%
|
-
|
|
Aug 12
2024
|
Christian O Henry |
BUY
Grant, award, or other acquisition
|
Direct |
16,115
+50.0%
|
-
|
|
Aug 12
2024
|
Aik Na Tan |
BUY
Grant, award, or other acquisition
|
Direct |
16,115
+50.0%
|
-
|
|
Aug 12
2024
|
Adrian Rawcliffe |
BUY
Grant, award, or other acquisition
|
Direct |
16,115
+50.0%
|
-
|
|
Jul 22
2024
|
Chandra Vargeese |
BUY
Exercise of conversion of derivative security
|
Direct |
68,210
+26.93%
|
$136,420
$2.48 P/Share
|
|
Apr 03
2024
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
15,630
-31.54%
|
$93,780
$6.17 P/Share
|
|
Dec 11
2023
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
1,000,000
+4.95%
|
$5,000,000
$5.0 P/Share
|
|
Dec 07
2023
|
Glaxosmithkline PLC > 10% Shareholder |
BUY
Open market or private purchase
|
Indirect |
3,300,000
+19.09%
|
$16,500,000
$5.0 P/Share
|
|
Aug 23
2023
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
37,062
-44.56%
|
$148,248
$4.75 P/Share
|
|
Feb 16
2023
|
Chandra Vargeese |
SELL
Open market or private sale
|
Direct |
10,249
-8.77%
|
$40,996
$4.03 P/Share
|
|
Feb 16
2023
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
29,400
-6.73%
|
$117,600
$4.04 P/Share
|
|
Feb 16
2023
|
Chris Francis |
SELL
Open market or private sale
|
Direct |
10,258
-11.4%
|
$41,032
$4.03 P/Share
|
|
Feb 16
2023
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,729
-10.87%
|
$38,916
$4.04 P/Share
|
|
Jun 16
2022
|
Ra Capital Management, L.P. |
BUY
Open market or private purchase
|
Indirect |
9,480,052
+35.53%
|
$18,960,104
$2.15 P/Share
|
|
May 05
2022
|
Chris Francis |
SELL
Open market or private sale
|
Direct |
10,867
-10.78%
|
$10,867
$1.72 P/Share
|
|
May 05
2022
|
Michael A. Panzara Officer |
SELL
Open market or private sale
|
Direct |
16,714
-13.28%
|
$16,714
$1.72 P/Share
|
|
May 05
2022
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
5,021
-5.6%
|
$5,021
$1.72 P/Share
|
|
May 05
2022
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
33,501
-7.12%
|
$33,501
$1.72 P/Share
|
|
May 05
2022
|
Chandra Vargeese |
SELL
Open market or private sale
|
Direct |
16,714
-13.08%
|
$16,714
$1.72 P/Share
|
|
May 04
2022
|
Chris Francis |
BUY
Grant, award, or other acquisition
|
Direct |
32,500
+24.37%
|
-
|
|
May 04
2022
|
Michael A. Panzara Officer |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+28.44%
|
-
|
|
May 04
2022
|
Kyle Moran Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
15,000
+14.34%
|
-
|
|
May 04
2022
|
Paul Bolno President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
92,500
+16.43%
|
-
|
|
May 04
2022
|
Chandra Vargeese |
BUY
Grant, award, or other acquisition
|
Direct |
50,000
+28.12%
|
-
|
|
Feb 16
2022
|
Michael A. Panzara Officer |
SELL
Open market or private sale
|
Direct |
10,603
-12.27%
|
$21,206
$2.31 P/Share
|
|
Feb 16
2022
|
Paul Bolno President and CEO |
SELL
Open market or private sale
|
Direct |
33,150
-8.07%
|
$66,300
$2.32 P/Share
|
|
Feb 16
2022
|
Chandra Vargeese |
SELL
Open market or private sale
|
Direct |
10,603
-11.99%
|
$21,206
$2.32 P/Share
|
|
Feb 16
2022
|
Chris Francis |
SELL
Open market or private sale
|
Direct |
10,123
-12.9%
|
$20,246
$2.31 P/Share
|
|
Feb 16
2022
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
9,204
-10.98%
|
$18,408
$2.31 P/Share
|
|
Apr 01
2021
|
Ra Capital Management, L.P. |
BUY
Other acquisition or disposition
|
Indirect |
970,025
+29.61%
|
$4,850,125
$5.61 P/Share
|
|
Mar 24
2021
|
Kyle Moran Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,930
+11.92%
|
$21,860
$2.48 P/Share
|
|
Feb 16
2021
|
Kyle Moran Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
1,722
-2.41%
|
$17,220
$10.57 P/Share
|
|
Feb 16
2021
|
Chandra Vargeese |
SELL
Open market or private sale
|
Direct |
3,145
-3.55%
|
$31,450
$10.57 P/Share
|
|
Feb 16
2021
|
Michael A. Panzara Officer |
SELL
Open market or private sale
|
Direct |
2,929
-3.28%
|
$29,290
$10.57 P/Share
|